Last reviewed · How we verify

NCT05092295

Head and Intraocular Trauma Tool for the Identification of Mild Traumatic Brain Injury

Active, enrolled Last updated 4 April 2025
What this trial tests

trial testing Head and Intraocular Trauma Tool in Brain Injuries, Traumatic in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 December 2021
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorRebiscan, Inc.
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment200
Start date1 December 2021
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Rebiscan, Inc.

Who can join

Adults 13 to 45, any sex, with Brain Injuries, Traumatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rebion has developed a device, the Rebion trauma tool (referred to as the head and intraocular trauma tool, or "HITT"), that detects ocular fixation and alignment using a binocular retinal scan. Preliminary data obtained from hospitalized patients with a clinically-confirmed traumatic brain injury (TBI) and uninjured controls indicates that the device can detect changes in ocular fixation, alignment, and saccades that are related to brain injury. This study seeks to evaluate the ability of the Rebion trauma tool to assess perturbations in eye movements resulting from TBI. The study will enroll 100 TBI patients and 100 controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Head and Intraocular Trauma Tool

Trials testing the same drug.

Other recruiting trials for Brain Injuries, Traumatic

Currently open trials in the same condition.

Other Rebiscan, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05092295.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing